Takeda Pharmaceutical Company Limited (TAK)
收市後：
| 前收市價 | 13.86 |
| 開市 | 13.83 |
| 買盤 | 0.00 x 1300 |
| 賣出價 | 0.00 x 2900 |
| 今日波幅 | 13.78 - 13.85 |
| 52 週波幅 | 12.58 - 15.08 |
| 成交量 | |
| 平均成交量 | 2,082,970 |
| 市值 | 44.254十億 |
| Beta 值 (5 年，每月) | 0.50 |
| 市盈率 (最近 12 個月) | 44.52 |
| 每股盈利 (最近 12 個月) | 0.31 |
| 業績公佈日 | 2024年10月31日 |
| 遠期股息及收益率 | 0.58 (4.22%) |
| 除息日 | 2024年3月27日 |
| 1 年預測目標價 | 16.01 |
BenzingaAlumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis (PsO) and in Phase 2 trials for systemic lupus erythematosus (SLE). HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30. Also Read: Newly-Lis
ZacksTAK or CTLT: Which Is the Better Value Stock Right Now?
TAK vs. CTLT: Which Stock Is the Better Value Option?
ZacksIs Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
